pillbase.ru

Imfinzi

Active substance: durvalumab

durvalumab

Centralised EU authorisationActive

Marketing holder: AstraZeneca AB

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • Durvalumab
    INJECTION, SOLUTION · DURVALUMAB 120 mg/2.4mL
    61434-038
    Catalent Indiana, LLC
  • IMFINZI
    INJECTION, SOLUTION · DURVALUMAB 500 mg/10mL
    0310-4611
    AstraZeneca Pharmaceuticals LP
  • IMFINZI
    INJECTION, SOLUTION · DURVALUMAB 120 mg/2.4mL
    0310-4500
    AstraZeneca Pharmaceuticals LP
  • durvalumab injection, solution
    INJECTION, SOLUTION · DURVALUMAB 500 mg/10mL
    61434-002
    Catalent Indiana, LLC
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208d-fc2e-7839-a3a6-9cc29356c654,01a1208f-8210-78a7-8f0a-5f40726d9a3c,01a12099-10fc-7aac-8bf8-16a7468653c9,01a1209b-8af4-73e1-b247-c04a10d26d07;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004771
Registration status
Active
ATC code
L01XC28
Sources
  • product · EMA · EMEA/H/C/004771 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004771 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004771 · Verified 2026-10-09